SIGMA HEALTHCARE LIMITED (SIG)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SIG - SIGMA HEALTHCARE LIMITED

FNArena Sector : Health & Nutrition
Year End: January
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -3.13
Index: ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.27

24 Jun
2024

-0.035

OPEN

$1.31

-2.68%

HIGH

$1.31

3,624,018

LOW

$1.27

TARGET
$1.057 -16.8% downside
Franking for last dividend paid out: 50%
OTHER COMPANIES IN THE SAME SECTOR
CLV . EBO . EXL . MCP .
FNARENA'S MARKET CONSENSUS FORECASTS
SIG: 1
Title FY23
Actual
FY24
Actual
FY25
Forecast
FY26
Forecast
EPS (cps) xxx 0.4 1.6 xxx
DPS (cps) xxx 1.0 1.0 xxx
EPS Growth xxx 100.0% 100.0% xxx
DPS Growth xxx 1.5% - 0.2% xxx
PE Ratio xxx N/A 77.6 xxx
Dividend Yield xxx N/A 0.8% xxx
Div Pay Ratio(%) xxx 223.9% 60.1% xxx

Dividend yield today if purchased 3 years ago: 1.64%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.75

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 28/03 - ex-div 0.5c (franking 50%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx0.4
DPS All xxxxxxxxxxxxxxx1.0
Sales/Revenue xxxxxxxxxxxxxxx3,322.1 M
Book Value Per Share xxxxxxxxxxxxxxx55.4
Net Operating Cash Flow xxxxxxxxxxxxxxx42.0 M
Net Profit Margin xxxxxxxxxxxxxxx0.14 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx0.67 %
Return on Invested Capital xxxxxxxxxxxxxxx0.53 %
Return on Assets xxxxxxxxxxxxxxx0.35 %
Return on Equity xxxxxxxxxxxxxxx0.67 %
Return on Total Capital xxxxxxxxxxxxxxx-8.40 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx27.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx10 M
Long Term Debt xxxxxxxxxxxxxxx127 M
Total Debt xxxxxxxxxxxxxxx137 M
Goodwill - Gross xxxxxxxxxxxxxxx89 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx356 M
Price To Book Value xxxxxxxxxxxxxxx1.87

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx4.7 M
Capex % of Sales xxxxxxxxxxxxxxx0.14 %
Cost of Goods Sold xxxxxxxxxxxxxxx3,132 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx262 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx14 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-0.3

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Shaw and Partners

xx/xx/xxxx

5

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

14/06/2024

5

Underperform

$0.90

-29.13%

Of the five concerns raised by the ACCC around the "merger" between Sigma Healthcare and Chemist Warehouse, Macquarie believes the structural change (raising barriers to entry) will be the most challenging to address.

The broker suggests the current risk/reward ratio of a positive outcome is too positively skewed, given increasing prospects of an altered deal.

The Underperform rating and 90c target are unchanged.

The ACCC expects to provide a decision on the proposed transaction on September 5.

FORECAST
Macquarie forecasts a full year FY25 dividend of 1.80 cents and EPS of 3.50 cents.
Macquarie forecasts a full year FY26 dividend of 2.40 cents and EPS of 4.70 cents.

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

SIG STOCK CHART